Nuvectis Pharma, Inc. most recently reported annual revenue of $0, a net loss of $26.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Nuvectis Pharma, Inc.: net profit was positive in 0 of 6 reported years; the most recent year shows a net loss of $26.0M.
Income Statement — 6 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
$0
Operating Expenses
$0
$13.0M
$19.0M
$23.0M
$20.0M
$28.0M
Operating Profit
$0
$-13.0M
$-19.0M
$-23.0M
$-20.0M
$-28.0M
Operating Margin
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Other Income
$0
$0
$0
$1.0M
$1.0M
$1.0M
Interest
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$0
$0
$0
Profit Before Tax
$0
$-13.0M
$-19.0M
$-22.0M
$-19.0M
$-26.0M
Tax
$0
$0
$0
$0
$0
$0
Net Profit
$0
$-13.0M
$-19.0M
$-22.0M
$-19.0M
$-26.0M
EPS
$0.00
$-1.09
$-1.51
$-1.43
$-1.11
$-1.32
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$6.0M
$7.0M
$4.0M
$5.0M
$4.0M
$6.0M
$6.0M
$7.0M
$8.0M
$8.0M
$6.0M
$7.0M
Operating Profit
$-6.0M
$-7.0M
$-4.0M
$-5.0M
$-4.0M
$-6.0M
$-6.0M
$-7.0M
$-8.0M
$-8.0M
$-6.0M
$-7.0M
Operating Margin
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$-6.0M
$-7.0M
$-4.0M
$-4.0M
$-4.0M
$-6.0M
$-5.0M
$-6.0M
$-7.0M
$-7.0M
$-6.0M
$-7.0M
Tax
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Profit
$-6.0M
$-7.0M
$-4.0M
$-4.0M
$-4.0M
$-6.0M
$-5.0M
$-6.0M
$-7.0M
$-7.0M
$-6.0M
$-7.0M
EPS
$-0.37
$-0.42
$-0.25
$-0.26
$-0.24
$-0.34
$-0.27
$-0.30
$-0.44
$-0.31
$-0.26
$-0.30
Over the 6 years reported for Nuvectis Pharma, Inc., cash stood at $32.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.46 times.
Balance Sheet — 6 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
Total Assets
$0
$7.0M
$20.0M
$19.0M
$19.0M
$32.0M
Current Assets
$0
$6.0M
$20.0M
$19.0M
$19.0M
$32.0M
Cash
$0
$6.0M
$20.0M
$19.0M
$19.0M
$32.0M
Inventory
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
Fixed Assets
$0
$0
$0
$0
$0
$0
Capital Work in Progress
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$0
$0
$0
Other Assets
$0
$0
$0
$0
$0
$0
Total Liabilities
$0
$18.0M
$6.0M
$7.0M
$9.0M
$13.0M
Current Liabilities
$0
$2.0M
$6.0M
$7.0M
$9.0M
$13.0M
Borrowings
$0
$0
$0
$0
$0
$0
Other Liabilities
$0
$18.0M
$6.0M
$7.0M
$9.0M
$13.0M
Equity
$0
$0
$0
$0
$0
$0
Reserves
$0
$-11.0M
$14.0M
$12.0M
$10.0M
$18.0M
For Nuvectis Pharma, Inc., operating cash flow was positive in 0 of 6 reported years; free cash flow in the latest year was negative at $16.0M; free cash flow was positive in 0 of 6 years; financing activities used $2.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 6 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$0
$-10.0M
$-14.0M
$-16.0M
$-12.0M
$-16.0M
Investing Cash Flow
$0
$0
$0
$0
$0
$0
Financing Cash Flow
$0
$0
$-4.0M
$10.0M
$0
$-2.0M
Net Cash Flow
$0
$6.0M
$14.0M
$-1.0M
$-1.0M
$13.0M
Free Cash Flow
$0
$-10.0M
$-14.0M
$-16.0M
$-12.0M
$-16.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
1.12
EV / EBITDA
-19.35
FCF Yield
-3.35%
Quick Ratio
1.68
Interest Coverage
—
Return 1Y
156.36%
Return 3Y
38.49%
Return 5Y
—
Nuvectis Pharma, Inc. (NVCT) financials — frequently asked questions
What is Nuvectis Pharma, Inc.'s annual revenue?
Nuvectis Pharma, Inc. (NVCT) reported annual revenue of $0 in its most recent fiscal year.
What is Nuvectis Pharma, Inc.'s net profit?
Nuvectis Pharma, Inc. (NVCT) reported a net loss of $26.0M in its most recent fiscal year.
What is NVCT EV/EBITDA?
Nuvectis Pharma, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -19.35. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.